Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.81 |
| ▸ | GSK3B | P49841 | 19/20 | 0.81 |
| ▸ | WNT1 | P04628 | 14/20 | 0.81 |
| ▸ | CLK2 | P49760 | 3/20 | 0.52 |
| ▸ | CLK3 | P49761 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19517209 | 0.90 | GSK3B (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20948842 | 0.89 | GSK3B (0.77) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20947737 | 0.87 | GSK3B (0.81) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20948778 | 0.86 | GSK3B (0.82) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20947445 | 0.85 | GSK3B (0.84) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20947945 | 0.83 | DYRK1A (0.82) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20949131 | 0.82 | DYRK1A (0.81) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20951702 | 0.81 | GSK3B (0.79) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916199 | 0.80 | DYRK1A (0.80) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916392 | 0.80 | GSK3B (0.83) | DYRK1AGSK3BWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | claimed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | claimed |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DKK1, WNT1 | DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885 |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | DYRK1A, DKK1, WNT1 | DYRK1A 1/4885GSK3B 19/4885WNT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.